International Symposium

2016 International Symposium for Tissue Phenomics®


EVENT DATE: Apr 26 - Apr 27, 2016
EVENT HOST: Definiens
EVENT LOCATION: Cambridge, MA-USA
EVENT WEB LINK: Event URL Coming Soon
EVENT AGENDA: Download

“The annual Symposium has become an institution for professionals in the biopharma industry seeking to move the needle on personalized medicine. Significant advancements are being made with Tissue Phenomics, and this event, which brings together some of the greatest minds in the industry, is critical to continuing the dialogue, collaboration and education needed for the progress of tissue-based diagnostics and immune-oncology.”
Thomas Heydler CEO Definiens

The 2016 International Symposium for Tissue Phenomics sold out this year with record high attendance.  Forward pushing industry experts and academic institutes came together to share and discuss their insights on topics such as immune-oncology and Tissue Phenomics.

Highlights

  • Introduction to Tissue Phenomics by Nobel Laureate and recent Kavli Prize recipient Professor Gerd Binnig
  • Thought-leading presentations on Tissue Phenomics, Immuno-oncology and Big Data
  • Industry experts panel discussions

Tissue Phenomics experts and key opinion leaders shared their insights on:

  • Tissue Phenomics
  • Understanding Immuno-Oncology
  • Tissue-based Immune Profiling
  • Selection & Understanding Target Identification
  • Tumor Microenvironment & Heterogeneity
  • Tissue-Based Patient Selection
  • Diagnostics in I-O
  • Big Data & Data Integration



Presentations

Tissue Phenomics – A Novel Big Data Approach in Pathology
Dr. Gerd Binnig, Nobel Laureate and Chief Technology Officer, Definiens, Munich, Germany

Prognostic and Predictive Significance of the Immunological Tumor Environment
Dr. Dirk Jäger, Director Medical Oncology, National Center for Tumor Diseases (NCT), University Medical Center Heidelberg, Heidelberg, Germany

COIN-ing Potential Clinically Translatable Markers in Metastatic Colorectal Cancer Through Tissue Phenomics
Dr. Ryan Hutchinson, Fellow in Molecular Pathology, Department of Pathology, Melbourne and Centre for Translational Pathology, University of Melbourne, Melbourne, Australia

Improving Therapy-Relevant Breast Cancer Protein Profiling Using Quantitative Immunofluorescence
Dr. Amy Ryder Peck, Senior Research Scientist, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Applying Tissue Phenomics to Colorectal Clinical Questions
Peter Caie, Senior Research Fellow, University of St. Andrews, Scotland

Novel Patient Stratification and Predictive Imaging Biomarkers for Development of Oncology Therapies
Dr. Belma Dogdas, Associate Principal Scientist, Merck, Rahway, New Jersey, USA

Use of Computer Tumor Tissue Imaging Algorithms to Assess the Role of Microenvironment in Melanoma Brain Metastases
Dr. Stergios Moschos, Clinical Associate Professor of Medicine The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Tissue Phenomics: From Biomarker Discovery to Clinical Diagnostic Assay Commercialization
Dr. Thomas Nifong, Executive Vice President, Diagnostic Tests, Definiens, Boston, Massachusetts, USA

Tissue Quality and Clinical Data: The Bottleneck for Drug and Biomarker Development
Dr. Hartmut Juhl, Chief Executive Officer, Indivumed GmbH, Hamburg, Germany

Measurement of Target Engagement and Pharmacodynamic Response to Investigational Anti-Cancer Agents in Phase 1 Clinical Trials
Dr. Robert J. Kinders, Senior Principal Scientist and Head, Pharmacodynamics, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA

Development of an Encapsulated Cell Replacement Therapy for Diabetes
Dr. Olivia G. Kelly, Director, Cell Biology, ViaCyte, Inc., San Diego, California, USA

Imaging and Analysis of RNA Biomarkers In Situ via RNAscope and SpotStudio
Dr. Xiao-Jun Ma, Chief Scientific Officer, Advanced Cell Diagnostics, Hayward, California, USA

Immunoscore / Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients for Clinical Trials
Dr. Carlo Bifulco, Medical Director, Oncologic Molecular Pathology and Pathology Informatics, Director, Translational Molecular Pathology, Providence Oregon Regional Laboratory & Earle A. Chiles Research Institute, Providence Health & Services, Portland, Oregon, USA

Immune Landscape and Immunoscore in the Era of Cancer Immunotherapies
Dr. Jérôme Galon, Research Director, INSERM, Head of Integrative Cancer Immunology Laboratory, INSERM, Paris, France

Implementation of Image Analysis for Biomarker Assessment of Pre-Clinical Tumor Models and Clinical Patient Samples
Dr. Belinda Cancilla, OncoMed Pharmaceuticals, Redwood City, California, USA

Companion Diagnostics: Aligning Development, Commercialization, and Market Access
Charles Mathews, Vice President, Boston Healthcare, Boston, Massachusetts, USA